Quest Diagnostics price target lowered to $117 from $125 at Barclays. Barclays analyst Jack lowered his price target for Quest Diagnostics to $117 saying the company’s analyst day was “clearly overshadowed” by its lower 2018 forecast. This has been a challenging year for Quest and the new issues are a “negative surprise,” Meehan tells investors in a research note. However, he sees merit to sticking with his Overweight thesis for the near-term given a “major 2019 catalyst as national payor networks open access.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.